Texas Children's Cancer and Hematology Center Featured Clinical Trials and Novel Therapies

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Gene transfer study available only at our Center for patients with refractory or recurrent B cell Acute Lymphoblastic Leukemia (B-ALL) with expression of CD19, CD20 and/or CD22

Eltrombopag for newly-diagnosed immune thrombocytopenia (ITP) in children

A novel treatment approach for newly-diagnosed ITP

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

Phase 1 therapy with manufactured autologous T-Cells for patients with recurrent T-cell leukemia or lymphoma

PBTC-059: A multi-center immunotherapy trial for children with relapsed/refractory ependymoma

TCH is leading a trial through the Pediatric Brain Tumor Consortium testing HER2 CAR T cells in children with relapsed/refractory ependymoma

GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors (GAIL-B)

Evaluating the safety, persistence and antitumor activity of T cells bearing a 2nd generation GD2.CAR

New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers

Phase 1 trial available only at our Center using 15.GPC3-CAR T-cells

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (CRIMSON)

Phase 1 trial of CD7-targeted CAR T-cells for children with relapsed or refractory T-cell leukemia or lymphoma

HEROS 3.0: New immunotherapy trial for children with relapsed/refractory sarcoma

Phase I clinical trial testing the combination of HER2 CAR T cells with checkpoint blockade

Immunotherapy trial for patients with relapsed/refractory Hodgkin's lymphoma or non-Hodgkin's lymphoma (RELY 30) 

Phase 1 trial using CD30.CAR T-cells to target relapsed, refractory Hodgkin's lymphoma or ALCL

Langerhan's cell histiocytosis (LCH): Vinblastine/prednisone vs. single therapy with cytarabine (LCH-REASON)

Leading a multi-institutional study for newly-diagnosed patients with LCH

Study of cobimetinib in patients with histiocytic diseases (NACHO COBI)

Research study for recurrent or refractory patients

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

Phase 2 trial designed to evaluate MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations

Evaluation of the Safety and Efficacy of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis

For participants with secondary hemophagocytic lymphohistiocytosis

EPIK-P2 (CBYL719F12201) / EPIK-P2: A Phase II double-blind study with an upfront, 16- week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

For patients with PIK3CA-related overgrowth spectrum (PROS)

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (ONITT)

Phase 1 study to determine dosing

Ranked #6 in Cancer

Proud to be ranked one of the best children’s cancer centers in the country by U.S. News & World Report for seven consecutive years.